Hernandez-Mondragon Oscar, Contreras Luis Garcia, Pineda Omar Michel, Blanco-Velasco Geraro, Murcio-Pérez Enrique
Instituto Mexicano del Seguro Social - Digestive Endoscopy, Ciudad de Mexico, Mexico.
Hospital de Especialidades Centro Medico Nacional Siglo, Mexico City, Mexico.
Endosc Int Open. 2021 Jun;9(6):E756-E766. doi: 10.1055/a-1386-3214. Epub 2021 May 27.
Treatment of octogenarian patients with achalasia with conventional treatments is effective but with compromised safety. Biodegradable stents (BS) are promising. We aimed to evaluate their safety, efficacy and clinical outcomes at early, mid and long-term in this population. Naïve or previously-treated achalasic octogenarian patients underwent to BS placement (BSP) between December, 2010 and November, 2011, and were followed-up for 9-years. A strict follow-up was performed. Thirty-two patients were included, (17 men [53.1 %]; median age 82 years [78-92]). BSP was performed in all patients. At 9y, 18/32 (56.2 %) completed protocol. Mean BSP time was 37.5±12.1 min and 34.4 % presented thoracic pain. At 1 m, six BS were migrated (18.7 %), requiring a second BSP fixed with hemoclips. At 3 m, twenty-three (72.8 %) completed degradation process. At 6 m, eighteen (56.2 %) presented clinical dysphagia, of whom 5/32 (15.6 %) presented stenotic-tissue hyperplasia, responding to balloon dilation in all cases. Pre-BSP Eckardt, Timed barium esophagram and integrated relaxation pressure improved post-BSP 6 m values (9 vs 2, p = 0.001; < 50 % = 93.8 % vs > 80 % = 81.5 %, p = 0.003 and 18.8 ± 3.2 vs 11.1 ± 2.6 mmHg, p = 0.001, respectively), and there were no significant changes up to 9y post-BSP. Esophagitis grade A or B was presented between 4.7 % to 11.2 % and controlled with PPI. After 9 years we had clinical success rates of 94.4 %, 72 %, and 65.4 % for time point evaluation, per protocol and intention to treat analysis, respectively. BSP represents a feasible alternative option in octogenarian patients with achalasia who are high risk with other treatments, presenting acceptable early, mid-, and long-term outcomes.
用传统疗法治疗老年贲门失弛缓症患者是有效的,但安全性有所降低。可生物降解支架(BS)很有前景。我们旨在评估其在该人群中的早期、中期和长期安全性、疗效及临床结果。2010年12月至2011年11月期间,未经治疗或先前接受过治疗的老年贲门失弛缓症患者接受了BS置入术(BSP),并进行了9年的随访。进行了严格的随访。纳入32例患者(17例男性[53.1%];中位年龄82岁[78 - 92岁])。所有患者均接受了BSP。9年后,18/32(56.2%)完成方案。平均BSP时间为37.5±12.1分钟,34.4%的患者出现胸痛。1个月时,6个BS发生移位(18.7%),需要用止血夹固定进行第二次BSP。3个月时,23个(72.8%)完成降解过程。6个月时,18个(56.2%)出现临床吞咽困难,其中5/32(15.6%)出现狭窄组织增生,所有病例均对球囊扩张有反应。BSP前的埃卡德评分、定时钡餐食管造影和综合松弛压在BSP后6个月时有所改善(9分对2分,p = 0.001;<50% = 93.8%对> >80% = 81.5%,p = 0.003;18.8±3.2对11.1±2.6 mmHg分别为p = 0.001),BSP后9年无显著变化。A级或B级食管炎发生率在4.7%至11.2%之间,用质子泵抑制剂控制。9年后,时间点评估、按方案分析和意向性分析的临床成功率分别为94.4%、72%和65.4%。BSP是其他治疗风险高的老年贲门失弛缓症患者的一种可行替代选择,具有可接受的早期、中期和长期结果。